Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Amlodipine and Olmesartan Medoxomil Tablets in strengths of 5 mg/20 mg, 5 mg/40 mg 10 mg/20 mg, and 10 mg/40 mg. The drug is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure.
The drug will be manufactured at the group’s formulations manufacturing facility at the Pharma SEZ, Ahmedabad. The group now has more than 150 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
